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ABSTRACT
Background Since publication of the human genome in
2003, geneticists have been interested in risk variant
associations to resolve the etiology of traits and complex
diseases. The International HapMap Consortium
undertook an effort to catalog all common variation
across the genome (variants with a minor allele
frequency (MAF) of at least 5% in one or more ethnic
groups). HapMap along with advances in genotyping
technology led to genome-wide association studies
which have identiﬁed common variants associated with
many traits and diseases. In 2008 the 1000 Genomes
Project aimed to sequence 2500 individuals and identify
rare variants and 99% of variants with a MAF of <1%.
Methods To determine whether the 1000 Genomes
Project includes all the variants in HapMap, we examined
the overlap between single nucleotide polymorphisms
(SNPs) genotyped in the two resources using merged
phase II/III HapMap data and low coverage pilot data
from 1000 Genomes.
Results Comparison of the two data sets showed that
approximately 72% of HapMap SNPs were also found in
1000 Genomes Project pilot data. After ﬁltering out
HapMap variants with a MAF of <5% (separately for
each population), 99% of HapMap SNPs were found in
1000 Genomes data.
Conclusions Not all variants cataloged in HapMap are
also cataloged in 1000 Genomes. This could affect
decisions about which resource to use for SNP queries,
rare variant validation, or imputation. Both the HapMap
and 1000 Genomes Project databases are useful
resources for human genetics, but it is important to
understand the assumptions made and ﬁltering
strategies employed by these projects.
INTRODUCTION
The ﬁeld of human genetics has rapidly developed in
the past few decades. The desire for precise genomic
mapping has encouraged the development of asso-
ciation studies, from genome-wide linkage studies to
both low and high throughput single nucleotide
polymorphism (SNP) genotyping and, most
recently, high throughput DNA sequencing. At each
stage of progression, the researcher has been better
able to narrow disease susceptibility genetic regions
and/or identify causal variants associated with
disease. The ﬁrst genetic linkage map was published
in 1987 and based on restriction fragment length
polymorphisms (RFLPs).
1 RFLPs are DNA poly-
morphisms that disrupt (by either creation or
destruction) restriction endonuclease recognition
sequences. In this ﬁrst map, only 393 bi-allelic RFLPs
were used. Second generation linkage maps were
based on microsatellites, which are short tandem
repeated DNA sequences present throughout the
genome. The ﬁrst published study using micro-
satellites included 814 polymorphic markers.
2 The
third generation linkage maps were created using
SNPs. These high density maps were developed by
the International HapMap Consortium (haplotype
mapping). HapMap aimed to compare genetic
sequences of different individuals and identify
chromosomal regions where genetic variants were
shared. These variations quickly became the core
around which genome-wide association studies
(GWAS) were built. Researchers believed that these
variations among individuals could explain the
heritability of common disease. After several years of
moderately successful GWAS, a group of researchers
decided that a more in-depth look at variation,
including rare variation, was necessary to explain
additional disease heritability. The 1000 Genomes
Project aimed to sequence 2500 individuals and
gather information on variants down to 1% allele
frequency with the goal of providing a more exten-
sive catalog of variation to the scientiﬁc community.
In addition to cataloging human variation, both
databases serve many other purposes. For example,
GWAS were possible because of the linkage
disequilibrium information calculated from the
SNPs in HapMap. Published sequencing studies are
often ﬁltered by variants in 1000 Genomes to
reduce the number of variants used in association
tests, since the individuals in 1000 Genomes are
presumably healthy controls and thus variants
detected in these data are unlikely of importance
for disease. Both of these resources have enhanced
the study design and analysis pipelines for common
and rare variant association studies.
The HapMap project was launched in October
2002 on the heels of the completion of the human
genome sequence. The project was designed to
build a database of common sequence variation, to
determine allele frequencies, and to empirically
determine the linkage disequilibrium relationships
across the genome. To date, there are three phases
of HapMap. The details are listed in table 1.
3 4
In 2008, the HapMap project catalog contained
3.5 million commonly occurring genetic variants
across several populations. The allele frequencies
and correlation patterns were critical for the
development and success of GWAS. However, to
expand the investigation of causal variants to
include rare variation, more research was required.
Using sequencing technology, researchers are able
to identify novel or rare variants. Sequencing
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Research and applicationsenables scientists to pinpoint functional variants from associa-
tion studies, improve the knowledge available to researchers
interested in evolutionary biology, and may lay the foundation
for predicting disease susceptibility and drug response. The 1000
Genomes consortium materialized to address these needs,
primarily by providing a sequence reference database. Their aim
has been to ‘provide a deep characterization of human genome
sequence variation as a foundation for investigating the rela-
tionship between genotype and phenotype.’ The pilot phase of
the project, which included three subprojects, provided the ﬁrst
data release. The subprojects were planned to achieve their aims
through evaluation of sequencing technology and to develop
analytical pipelines for alignment, quality control, data
management, and statistical analysis.
5 Details about the pilot
data from the 1000 Genomes Project are shown in table 2.
Review of the pilot data shows that the project successfully
catalogs the vast majority of common variation. Durbin et al
reported that over 95% of the currently accessible variants found
in any individual were present in the pilot data.
6
To date (August 2011), the full 1000 Genomes Project data
includes SNP calls, exome alignments, and genotypes for 1185
individuals. The end goal is to sequence approximately 2500 de-
identiﬁed subjects from 25 populations worldwide using next-
generation sequencing technology. In the ‘low-coverage’ full project
data, the current coverage estimate is 7.73 (64.2) and includes 15
world populations.
6 In this analysis, we downloaded an earlier
release of the full project data (released October 2010) which
included 629 individuals from 15 world populations (see table 3).
Both HapMap and 1000 Genomes have proved very valuable
in the ﬁeld of human genetics and have paved the way for:
< Designing and reﬁning genotyping platforms (HapMap) and
next-generation sequencing technologies (1000 Genomes)
< The development of many computational pipelines
< The creation of a control for comparison to be used with
developing technology
< Deﬁning linkage disequilibrium patterns and consequently
the ability to choose tag SNPs (integral for GWAS)
< Unbiased allele frequency estimates
< Estimating ancestry proportions
< Identifying population substructure
< Studying genomic structure, recombination rates, and muta-
tion rates.
These resources are invaluable tools in genetics research and
their functionality has quite a bit of overlap. When considering
which database to reference, one might base one’s decision on
the newest release, total number of variants, or even ethnicities
included. For example, if a researcher’s interest was rare variants,
he/she might automatically assume that data from the 1000
Genomes Project would be the variation catalog of choice. The
1000 Genomes Project aimed to provide characterization of over
95% of variants in accessible genomic regions that have an allele
frequency of 1% or higher.
6 In the previous example, presuming
that the 1000 Genomes Project data included more rare variants
than HapMap would be a correct assumption; the 1000
Genomes Project pilot data do indeed capture more rare varia-
tion than HapMap. However, not all rare variants found in
HapMap have been found in the 1000 Genomes Project catalog.
Therefore, if one is interested in rare variants, it might be
beneﬁcial to investigate both resources. An example of this is
shown in ﬁgure 1, which shows a screen shot from the NCBI
browser (taken in October 2010) of a region on chromosome 7. It
lists the known variants by chromosome position, rs id, func-
tional change, alleles, and many other identifying characteristics.
It also includes a validation column which provides links and
details about the validation status of each given variant. Of
particular interest is variant rs2072413. It was validated in
HapMap but was not sequenced by the 1000 Genomes Project
(at this time, only pilot data from 1000 Genomes were available
on NCBI). If this SNP was of interest, it would be important to
consider the HapMap data, including rare variants. This was
somewhat surprising, and we felt that it might be pertinent to
determine how pervasive the differences were between HapMap
and 1000 Genomes Project data.
The goal of this work is to quantify the number of variants
(with particular focus on rare variants) that were cataloged in
HapMap but not found in 1000 Genomes data. The initial phase
of this research was performed using 1000 Genomes Project low
coverage data in CEU and YRI individuals. The follow-up phase
was carried out using the full data from the 1000 Genomes
Project which contained sequence data from 174 individuals
from African populations, 283 individuals from European
populations, and 195 individuals from Asian populations (see
breakdown by ethnicity in table 3).
METHODS
Overlap quantiﬁcation between HapMap and 1000 Genomes
Project pilot data
To compare the two resources, we downloaded the data from each
database directly, and established data tables within a MySQL
relational database system. We ran queries to examine the overlap
between the two resources. Speciﬁcally, we downloaded the
merged phase II+phase III (release 28) HapMap data for CEU and
YRI (http://hapmap.ncbi.nlm.nih.gov/downloads/frequencies/
2010-08_phaseII+III/). We downloaded 1000 Genomes Project
pilot data VCF ﬁles for CEU and YRI from the 1000 Gen-
omes Project website (ftp://ftp-trace.ncbi.nih.gov/1000genomes
/ftp/pilot_data/release/2010_07/low_coverage/snps). Genomic
Table 1 HapMap details
No. of SNPs
genotyped Targeted SNPs Populations studied
Phase I 1 million Prioritized coding SNPs to attain
1 SNP for each 5 kb region
CEU, YRI, CHB, JPT
Phase II 3 million Prioritized non-synonymous
SNPs in coding regions
CEU, YRI, CHB, JPT
Phase III 1.4 million Prioritized rare variants CEU, YRI, CHB, JPT,
ASW, CHB, GIH, LWK,
MXL, MKK, TSI
SNP, single nucleotide polymorphism.
Table 2 Details for three pilot projects initiated by the 1000 Genomes
Project
Pilot data sets Populations Samples Coverage
Trio 2 6 20e403
Low coverage 4 179 2e43
Exon (8140 exons, w5% of exome) 7 697 20e503
Table 3 Details for 1000 Genomes Project full project data (sequence
index 2010.08.04)
Continental groups Ethnicity breakdown Total
AFR 78 YRI+67 LWK+24 ASW+5 PUR 174
EUR 90 CEU+92 TSI+43 GBR+36 FIN+17
MXL+5 PUR
283
ASN 68 CHB+25 CHS+84 JPT+17 MXL 194
Total number of unique individuals 629
AFR, African; ASN, Asian; EUR, European.
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Research and applicationscoordinates of SNPs from both data sets are from NCBI build 36.
We compared the overlap of variants between the two resources
using NCBI 36 chromosome and base pair location. Query results
contained the number and percentage of variants common
between both databases. Then using a simple calculation, we
obtained the number and percentage of HapMap variants missing
from the 1000 Genomes Project database. We discuss the number
of HapMap variants that were exclusive to HapMap below.
Overlap quantiﬁcation between HapMap and 1000 Genomes
Project full data
In the second step of this analysis, we used the merged phase II
+phase III (release 28) HapMap data for CEU and YRI (inde-
pendently). Since the data were build 36 and HapMap, to date,
has not released build 37 data, yet 1000 Genomes Project full
data is released in build 37. Thus, we ran the HapMap data
through the UCSC LiftOver
7 algorithm to obtain the HapMap
data in build 37 coordinates. Second, we used the 1000 Genomes
Project full project data from the 1000 Genomes website (the
available version from August 2010). The data were combined
data from several ethnicities (see table 3). We kept the complete
list (including all individuals for the full project data) of variants
for comparison. It is important to note that the combined
ethnicity data set from 1000 Genomes is different from the
single ethnicity download performed in the pilot analysis.
First, we compared CEU HapMap variants with the full project
data, and then performed the same analysis comparing YRI
HapMap variants with the full project data. The output included
the number of variants that were common between HapMap and
1000 Genomes Project full project data. From this, we obtained
the number and percentage of variants exclusive to HapMap.
RESULTS
In the ﬁrst stage of analysis, we compared HapMap and
1000 Genomes Project pilot data. When comparing the CEU
populations, only 69% of variants in HapMap were also found in
1000 Genomes Project pilot data. When comparing the YRI
populations, only 75% of variants in HapMap were also found in
1000 Genomes Project pilot data. These percentages were much
lower than the expected 90%e95% overlap.
First, we wanted to investigate which types of alleles were the
uncommon variants excluded from 1000 Genomes Project pilot
data. The incorporation efﬁciency of many sequencing reactions
is greatly affected by strand base composition and more complex
sequence, such as repetitive and/or GC rich regions, can lead to
higher error rates. Therefore, if the missing variants were
primarily GC rich, missingness in 1000 Genomes pilot data
might be due to sequencing errors. Therefore, we plotted the
reference allele type frequency (for the HapMap exclusive data)
by chromosome (see ﬁgure 2).
Next, we investigated the distribution of allele frequencies. A
quick query showed that HapMap contains many monomorphic
alleles for a given population. 1000 Genomes Project pilot data
do not retain monomorphic alleles in the data. After ﬁltering out
the monomorphic variants in the CEU individuals, 93% of
variants in HapMap were also found in 1000 Genomes Project
pilot data. After ﬁltering out the monomorphic variants in YRI
individuals, 92% of variants in HapMap were also found in 1000
Genomes Project pilot data. Figure 3 shows the distribution of
HapMap exclusive reference allele frequencies by percentage of
exclusive variants.
In the CEU population, approximately 75% of the exclusive
variants (those missing from 1000 Genomes Project pilot data)
had a reference allele frequency of >98%, which corresponds to
a minor allele frequency (MAF) of <2%. In the YRI population,
approximately 55% of the exclusive variants had a reference allele
frequency of >98%, which corresponds to a MAF of <2%.
Figure 3 shows that ‘missing’ variants in 1000 Genomes Project
pilot data are due to alleles of low frequency. After ﬁltering out
monomorphic and uncommon (<5% MAF) variants, the number
Figure 1 Variants in HapMap and 1000 Genomes Project data. The left box shows an enhanced screenshot from the NCBI browser. rs2072413
shows that variants in HapMap are not always found in 1000 Genomes Project data. For reference, the validation status descriptions are shown in the
box on the right. SNP, single nucleotide polymorphism.
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Research and applicationsof exclusive variants fell to 1% and 2% in CEU and YRI popu-
lations, respectively. The data are shown in table 4.
To further illustrate the point, ﬁgure 4 shows the distribution
of total HapMap variants compared to those also found in 1000
Genomes pilot data. The data used in this example are from
chromosome 1 in CEU data. The tan bars represent the total
number of variants in HapMap (if applicable, after ﬁltering). The
green bars represent the total number of variants in HapMap
that are common to 1000 Genomes Project pilot data. For
reference, the total number of variants on chromosome 1 in the
1000 Genomes Project pilot data is 605756 (which is shown as
a gray line in the ﬁgure).
To be thorough, we performed a similar analysis to that
described above, but instead compared HapMap data with the
1000 Genomes full project data. The results are shown in table 5.
DISCUSSION
In the initial stage of analysis, we compared the variants
between HapMap and 1000 Genomes Project pilot data in both
the CEU and YRI populations. We expected complete overlap of
the HapMap variants in 1000 Genomes and were surprised that
30% of the HapMap variants were missing. We were curious as
to why some variants are ‘missing,’ and if they were missing at
random in the 1000 Genomes Project pilot data. We ﬁrst
examined SNP coverage, with the hypothesis that the low-
coverage pilot data (2e63 coverage) simply could not sequence
the ‘missing’ variants with enough conﬁdence to meet quality
control standards. Second, we considered the possibility that the
‘missing’ variants were false positive discoveries in HapMap.
However, this was unlikely since the HapMap SNPs are far
better validated than those from 1000 Genomes.
8 Another factor
Figure 2 Reference allele frequency in
the HapMap exclusive data, by
chromosome in CEU (A) and YRI (B).
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variants in a particular region of the chromosome or do they
have particular characteristics or alleles? We visualized the
missing variants across the chromosome to see if there were
peaks around certain locations (ie, in GC rich regions or near the
centromere or telomere). There was no visible pattern of
‘missingness’ along the length of the chromosome (data not
shown). Could these results be replicated in other populations?
We wanted to investigate if there was a pattern of allele type in
the HapMap exclusive data. Figure 2 shows the reference allele
type frequency by chromosome. There are more ‘missing’ GC
(share triple hydrogen bond) pairs than AT (share double
hydrogen bond) pairs across both populations and in every
chromosome. However, this is representative of the distribution
of allele types in the human genome and so is not surprising.
Next, we investigated the allele frequency distribution of the
missing variants. We started by removing monomorphic and very
rare variants (MAF <0.01). As shown in ﬁgures 3 and 4, and table
3, only after ﬁlters are used to remove ﬁxed or uncommon vari-
ants in HapMap, do 1000 Genomes Project pilot data cover the
expected number of variants in HapMap (99%). This is surprising
since the 1000 Genomes Project reports that the pilot data cover
95% of all variation down to 1% allele frequency (and down to
0.1% allele frequency in coding regions). Therefore, most
HapMap exclusive variants were ﬁxed or uncommon variants.
This raises two important points: (a) HapMap contains mono-
morphic alleles; and (b) HapMap contains uncommon variants
that have not been validated in 1000 Genomes Project pilot data.
To address the ﬁrst point, it is surprising that a catalog of vari-
ation contains alleles that are themselves not variable. This could
be a result of how the data are stored; many of these variants are
undoubtedly polymorphic in other populations. SNPs are popu-
lation speciﬁc, but, for example, if one downloads CEU variants
from the HapMap website, monomorphic SNPs (speciﬁcally
monomorphic in the CEU population) are not automatically
ﬁltered out. Note that this is the case even in imputed lists that
are available online. To be included in an imputation SNP list,
SNPs must pass quality control in every population and be
polymorphic in at least one population. One can use HapMart,
which is an extension of HapMap that allows the user to apply
various ﬁlters to the data before download (one of which is to
ﬁlter out monomorphic and/or rare variants). As for the second
point, we cannot assume that 1000 Genomes Project pilot data
include all of the variation cataloged in HapMap. The rare vari-
ants could have been completely missed or eliminated during
quality control testing. In order to determine if this is a function
of coverage or of number of individuals sequenced, this study was
repeated using the 1000 Genomes full project data.
Because there were still quite a few HapMap variants missing
from the 1000 Genomes resource, we decided to perform
a second analysis using the 1000 Genomes Project full project
data. One hypothesis was that these missing variants were due
to the low coverage data being incomplete (only 60 individuals
to represent a population). With more individuals, perhaps some
of the missing rare variants would be captured. This was
certainly the case, when the raw data from the two analyses
were compared. In the ﬁrst analysis (using pilot data) over 30%
of the variants listed in HapMap were missing from the 1000
Genomes pilot data. In the second analysis, only a little over
10% of the variants listed in HapMap were missing from the
1000 Genomes full project data. After a ﬁlter was incorporated
to remove ﬁxed and then additionally rare variants, the overlap
was approximately 99% in both cases (see table 5). This most
likely can be explained in two ways. First, the results suggest
that the 1000 Genomes Project full data are more complete in
terms of cataloging rare variants. Second, the multiethnic data
from the 1000 Genomes Project include more rare variants than
any one single population. The latter is certainly true, and
perhaps some of the variants missing in the pilot data for CEU
or YRI are more prevalent in other ethnicities, and so were more
likely to be included in the multiethnic full data.
The ﬁeld of human genetics is quickly adopting the usage of
online database resources and catalogs. Since the start of
HapMap in 2003 to the expected completion of the 1000
Genomes Project in 2012, these research assets have greatly
altered the course of genetics research and the community’s
resolution to deﬁne genetic inﬂuences on disease. However, it is
important to be vigilant of the validity of information, partic-
ularly in very competitive and fast-paced ﬁelds of research.
Figure 3 Distribution of reference allele frequencies (most often the
major allele frequency) of HapMap (HM) exclusive variants after ﬁltering
out any ﬁxed alleles in CEU (A) and YRI (B) populations.
Table 4 Comparison of HapMap and 1000 Genomes Project pilot data
Population Raw data
Filtered out ﬁxed alleles
(ﬁxed: AF[0o r1 )
Filtered out uncommon
alleles (uncommon:
AF<0.05 or >0.95)
CEU 0.6858 0.9314 0.9894
YRI 0.7543 0.9234 0.9841
The table shows the percentage of variants in HapMap that were also represented in 1000
Genomes (and therefore, were common to both). The ﬁrst column indicates the two
populations used in this study; the second column shows the calculated percentage (of
HapMap) common to both databases using the raw data; the third and fourth columns
indicate how the HapMap list of variants was ﬁltered before comparison.
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Research and applicationsRecently, Nothnagel et al published a review of three common
next-generation sequencing technologies using aligned DNA
sequences from two HapMap samples included in the 1000
Genomes Project. After removing the validated HapMap vari-
ants (present in HapMap), they statistically evaluated the
validity of novel single-nucleotide variants. They found an
alarming proportion of false positives (3%e17%); however, that
number was reduced to 1%e3% if called by more than one
platform.
8 Next-generation sequencing provides both incredible
opportunities and complex challenges for researchers. Due to
cost and technology requirements (equipment, database
resources, and technicians), many scientists will opt to pay
another institution or group to generate their sequence data. In
addition, more reference data sets will likely become available to
researchers (1000 Genomes Project). In both of these scenarios,
the researcher will have little to no control over data generation
and quality control. Knowledge of error estimates and validity
for ‘novel’ single-nucleotide variants will be incredibly important
to those performing statistical analysis.
8
CONCLUSION
Next-generation sequencing projects are revolutionizing our
understanding of genetic variation. The quality of data from the
next-generation technology and the availability of analysis tools
are both rapidly increasing. Just considering the pilot data from
the 1000 Genomes Project, this new resource has provided the
location, allele frequency, and local haplotype structure of
approximately 15 million SNPs. The number of novel variants is
constantly increasing and many believe that the 1000 Genomes
Project could potentially overshadow the utility of HapMap. In
this study, we compared variants in HapMap with those present
in 1000 Genomes data (both in the low-coverage pilot and full
data sets). We found that 1000 Genomes Project pilot data only
cover 99% of variants in the merged phase II+phase III HapMap
database if one ﬁlters out uncommon (<5% MAF) and mono-
morphic variants. If these ﬁlters are not applied, most of the
variants only seen in HapMap have a MAF of <5%. Performing
the comparison using the 1000 Genomes Project full project data
instead of pilot data, we found considerably more overlap
between the two resources. This has implications for those
interested in performing imputation with uncommon variants as
well researchers interested in SNP validation or researching
a candidate gene. We know that rare variant frequencies are
heavily dependent on the population. Perhaps the most thorough
imputation list would be a combined data set between the two
catalogs. There are several other reasons researchers might prefer
a comprehensive list of variants: SNP validation, candidate gene
research, and to better understand ancestry and evolution. Both
of these resources are incredibly powerful and useful in the ﬁeld
of genetics, so it is important to consider the limitations of the
technology and how each might best beneﬁt your research.
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variants left after an allele frequency
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Table 5 Comparison of HapMap and 1000 Genomes Project full project
data
Population Raw data
Filtered out ﬁxed alleles
(ﬁxed: AF[0o r1 )
Filtered out uncommon
alleles (uncommon:
AF<0.05 or >0.95)
CEU 0.8784 0.9884 0.9930
YRI 0.8778 0.9859 0.9932
The table shows the percentage of variants in HapMap that were also represented in 1000
Genomes (and therefore, were common to both). The ﬁrst column indicates the two
populations used in this study; the second column shows the calculated percentage (of
HapMap) common to both databases using the downloaded data; the third and fourth
columns indicate how the HapMap list of variants was ﬁltered before comparison.
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